Cargando…

Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer

BACKGROUND: Radiation therapy (RT) is a crucial modality for the local control of pelvic cancer (PC), but the effect of pelvic RT on the development of secondary malignancy is still unclear. This study aimed to identify the relationship between radiation therapy received for the treatment of primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuofeng, Wei, Ran, Yu, Guanhua, Liu, Hengchang, Chen, Tianli, Guan, Xu, Wang, Xishan, Jiang, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449132/
https://www.ncbi.nlm.nih.gov/pubmed/36091158
http://dx.doi.org/10.3389/fonc.2022.982792
_version_ 1784784224844251136
author Li, Shuofeng
Wei, Ran
Yu, Guanhua
Liu, Hengchang
Chen, Tianli
Guan, Xu
Wang, Xishan
Jiang, Zheng
author_facet Li, Shuofeng
Wei, Ran
Yu, Guanhua
Liu, Hengchang
Chen, Tianli
Guan, Xu
Wang, Xishan
Jiang, Zheng
author_sort Li, Shuofeng
collection PubMed
description BACKGROUND: Radiation therapy (RT) is a crucial modality for the local control of pelvic cancer (PC), but the effect of pelvic RT on the development of secondary malignancy is still unclear. This study aimed to identify the relationship between radiation therapy received for the treatment of primary PC and subsequent secondary bladder cancer (SBC). METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (from 1975 to 2015) was queried for PC. Fine-gray competing risk regression and Cox regression analyses were employed to assess the cumulative incidence of SBC. Poisson regression and multiple primary standardized incidence ratios (SIR) were used to evaluate the radiotherapy-associated risk for patients receiving RT. Subgroup analyses of patients stratified by latency time since PC diagnosis, calendar year of PC diagnosis stage, and age at PC diagnosis were also performed. Overall survival (OS) was compared among different treatment groups with SBC by Kaplan–Meier analysis. RESULTS: A total of 318,165 observations showed that the primary cancers were located in pelvic cavity, 256,313 patients did not receive radiation therapy (NRT), 51,347 patients who underwent external beam radiation therapy (EBRT), and 10,505 patients receiving a combination of EBRT and brachytherapy (EBRT–BRT) who developed SBC. Receiving two types of radiotherapy was strongly consistent with a higher risk of developing SBC for PC patients in Fine-Gray competing risk regression (NRT vs. EBRT, adjusted HR= 1.71, 95% CI: 1.54-1.90, P<0.001; NRT vs. EBRT–BRT, adjusted HR= 2.16, 95% CI: 1.78-2.63, P<0.001). The results of the dynamic SIR and Poisson regression analysis for SBC revealed that a slightly increased risk of SBC was observed after RT in the early latency and was significantly related to the variations of age at PC diagnosis and decreased with time progress. For OS, the SBC after NRT, SBC after EBRT, and SBC after EBRT-BRT of 10-year survival rates were 37.9%, 29.2%, and 22.2%, respectively. CONCLUSION: Radiotherapy for primary PC was associated with higher risks of developing SBC than patients unexposed to radiotherapy. Different pelvic RT treatment modalities had different effects on the risk of SBC.
format Online
Article
Text
id pubmed-9449132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94491322022-09-08 Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer Li, Shuofeng Wei, Ran Yu, Guanhua Liu, Hengchang Chen, Tianli Guan, Xu Wang, Xishan Jiang, Zheng Front Oncol Oncology BACKGROUND: Radiation therapy (RT) is a crucial modality for the local control of pelvic cancer (PC), but the effect of pelvic RT on the development of secondary malignancy is still unclear. This study aimed to identify the relationship between radiation therapy received for the treatment of primary PC and subsequent secondary bladder cancer (SBC). METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (from 1975 to 2015) was queried for PC. Fine-gray competing risk regression and Cox regression analyses were employed to assess the cumulative incidence of SBC. Poisson regression and multiple primary standardized incidence ratios (SIR) were used to evaluate the radiotherapy-associated risk for patients receiving RT. Subgroup analyses of patients stratified by latency time since PC diagnosis, calendar year of PC diagnosis stage, and age at PC diagnosis were also performed. Overall survival (OS) was compared among different treatment groups with SBC by Kaplan–Meier analysis. RESULTS: A total of 318,165 observations showed that the primary cancers were located in pelvic cavity, 256,313 patients did not receive radiation therapy (NRT), 51,347 patients who underwent external beam radiation therapy (EBRT), and 10,505 patients receiving a combination of EBRT and brachytherapy (EBRT–BRT) who developed SBC. Receiving two types of radiotherapy was strongly consistent with a higher risk of developing SBC for PC patients in Fine-Gray competing risk regression (NRT vs. EBRT, adjusted HR= 1.71, 95% CI: 1.54-1.90, P<0.001; NRT vs. EBRT–BRT, adjusted HR= 2.16, 95% CI: 1.78-2.63, P<0.001). The results of the dynamic SIR and Poisson regression analysis for SBC revealed that a slightly increased risk of SBC was observed after RT in the early latency and was significantly related to the variations of age at PC diagnosis and decreased with time progress. For OS, the SBC after NRT, SBC after EBRT, and SBC after EBRT-BRT of 10-year survival rates were 37.9%, 29.2%, and 22.2%, respectively. CONCLUSION: Radiotherapy for primary PC was associated with higher risks of developing SBC than patients unexposed to radiotherapy. Different pelvic RT treatment modalities had different effects on the risk of SBC. Frontiers Media S.A. 2022-08-24 /pmc/articles/PMC9449132/ /pubmed/36091158 http://dx.doi.org/10.3389/fonc.2022.982792 Text en Copyright © 2022 Li, Wei, Yu, Liu, Chen, Guan, Wang and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Shuofeng
Wei, Ran
Yu, Guanhua
Liu, Hengchang
Chen, Tianli
Guan, Xu
Wang, Xishan
Jiang, Zheng
Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title_full Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title_fullStr Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title_full_unstemmed Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title_short Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
title_sort risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449132/
https://www.ncbi.nlm.nih.gov/pubmed/36091158
http://dx.doi.org/10.3389/fonc.2022.982792
work_keys_str_mv AT lishuofeng riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT weiran riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT yuguanhua riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT liuhengchang riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT chentianli riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT guanxu riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT wangxishan riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer
AT jiangzheng riskandprognosisofsecondarybladdercancerafterradiationtherapyforpelviccancer